mRNA-1189 Epstein-Barr Virus Vaccine Description
Moderna Inc. messenger RNA (mRNA) vaccine candidate mRNA-1189 contains four mRNAs that encode Epstein-Barr Virus (EBV) envelope glycoproteins (gH, gL, gp42, gp220), which mediate viral entry into B-cells (a type of immune system cells) and epithelial surface cells, the primary targets of EBV infection. mRNA-1189 seeks to prevent the development of infectious mononucleosis and EBV infection. The viral proteins in mRNA-1189 are expressed in their native membrane-bound form for recognition by the Human Immune System. Similar to Moderna's CMV vaccine candidate (mRNA-1647), mRNA-1189 contains four mRNAs
While EBV infection in early childhood is predominantly asymptomatic, primary infection in adolescence can lead to infectious mononucleosis (IM), a clinical syndrome including fever, fatigue, sore throat, and lymphadenopathy. IM can debilitate patients for weeks to months, sometimes requiring hospitalization of severe complications such as splenic rupture and significant airway compromise. Long term, EBV is associated with certain lymphoproliferative disorders, a higher risk of developing cancers and autoimmune diseases, and an approximately 32-fold increased risk of developing multiple sclerosis.
The Company confirmed on May 4, 2022, that it expects to test the vaccine in patients with multiple sclerosis, and in transplant patients to prevent post-transplant lymphoproliferative disorder (PTLD). As of May 5, 2022, the U.S. FDA had not authorized an EBV vaccine.
Most recently, Massachusetts-based Moderna's capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic. Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology, and manufacturing. It has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. To learn more, visit www.modernatx.com.
mRNA-1189 Epstein-Barr Virus Vaccine Indication
The Epstein-Barr virus is a herpesvirus family member. More than 90% of the adult population globally has been infected by the Epstein-Barr virus. Potential future indications may be the prevention of EBV reactivation in other types of conditions such as post-transplant lymphoproliferative disease. EBV is a common viral infection with 83% of Americans seropositive by 19 years. It is spread through bodily fluids (e.g., saliva). EBV is responsible for approximately 90% of the one million cases of IM each year in the U.S. As a latent virus, EBV remains in the body for life after infection and can lead to lifelong medical conditions, which causes significant direct and indirect costs to the healthcare system. For example, EBV is associated with a 4- to 10-fold risk of developing multiple sclerosis and development of certain lymphoproliferative disorders, cancers, and autoimmune diseases.
EBV is also associated with other malignancies, including gastric carcinoma, nasopharyngeal carcinoma, and Burkitt lymphoma. Overall, EBV is estimated to have caused ~1-2% of all global cancers in 2021 and is responsible for 140-200,000 deaths per year (est.). In addition, EBV also causes Post-transplant lymphoproliferative disorder, a potentially fatal complication affecting allogeneic hematologic stem cell transplant recipients and, to a less extent, solid organ transplants.
"Epstein-Barr Virus is one of the most common viral infections in the world, and although it causes infectious mononucleosis, which impacts millions of adolescents globally, no vaccine is currently available. As a result, adolescents who develop infectious mononucleosis are frequently absent from school for weeks and even months at a time, impacting the quality of their education and their families," said Stéphane Bancel, CEO of Moderna.
Epstein-Barr Virus and Multiple Sclerosis
Multiple sclerosis is likely caused by infection with the Epstein-Barr virus, according to a study published by Harvard T.H. Chan School of Public Health researchers on January 13, 2022. Scientists, led by Alberto Ascherio from the Harvard TH Chan School of Public Health, examined more than 10m blood samples from U.S. military personnel collected over 20 years and identified that those who became infected with EBV were 32 times more likely to later develop MS.
Epstein-Barr Virus and Cancer
Researchers estimated that EBV-related cases from six cancers accounted for over 200,000 new cases and 130,000 deaths in 2020. This review highlights the significant global impact of EBV-related cancers and extends the spectrum of diseases that could benefit from an EBV-specific therapeutic.
mRNA-1189 Epstein-Barr Virus Vaccine News 2022
May 4, 2022 - Moderna, Inc. reported the first quarter of 2022 revenues were $6.1 billion; GAAP net-income of $3.7 billion.
March 24, 2022 - Moderna Inc. confirmed it is currently conducting a Phase 1 trial that is in the expansion phase following a favorable initial safety review. Additionally, a therapeutic vaccine (mRNA-1195) against long-term EBV sequelae, such as MS and post-transplant lymphoproliferative disease, is in preclinical development.
February 24, 2022 - Moderna, Inc. reported full-year 2021 revenues of $18.5 billion.
January 13, 2022 - A longitudinal analysis revealed a high prevalence of Epstein-Barr virus-associated with multiple sclerosis. The risk of MS increased 32-fold after infection with EBV but was not increased after infection with other viruses, including the similarly transmitted cytomegalovirus. Serum levels of neurofilament light chain, a biomarker of neuroaxonal degeneration, increased only after EBV seroconversion. These findings cannot be explained by any known risk factor for MS and suggest EBV as the leading cause of MS.
January 5, 2022 - Moderna announced today that they had dosed their first participant in Eclipse, a phase 1 study Clinicaltrials.gov ID NCT05164094 of their EBV vaccine candidate.
mRNA-1189 Epstein-Barr Virus Vaccine Clinical Trials
Moderna has begun dosing their first participant in the Phase 1 clinical trial. Clinical Trial NCT05164094: A Study of an Epstein-Barr Virus Candidate Vaccine, mRNA-1189, in 18- to 30-Year-Old Healthy Adults. Participants will receive three intramuscular (IM) injections of mRNA-1189 at Dose Level 1 on Days 1, 57, and 169.
Contact: Moderna Clinical Trials Support [email protected].